Lineage Cell Therapeutics, Inc. - LCTX STOCK NEWS

Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the Raymond James 2021 Human Health Innovation Conference on June 22, 2021, at 1:20 p.m. ET. Investors can access the presentation live and archived on the company's Events and Presentations webpage. Lineage develops allogeneic cell therapies targeting significant medical needs, with products like OpRegen, OPC1, and VAC2 currently in Phase 1/2a clinical trials.

Lineage Cell Therapeutics (LCTX) announced its inclusion in the Russell 3000 and Russell Microcap Indexes, effective June 28, 2021. This recognition highlights the company's advancements in developing allogeneic cell therapies. The Russell Indexes encompass the largest U.S. stocks, with membership potentially enhancing investor outreach and liquidity. CEO Brian M. Culley stated that this achievement reflects the company’s progress and aims to capitalize on the growing field of cell therapy. The Russell Indexes influence substantial assets, with about $10.6 trillion benchmarked against them.

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) announced a webinar on June 10, 2021, at 4 PM ET, featuring experts discussing age-related macular degeneration (AMD). The company reported successful retinal tissue restoration in three patients from its OpRegen Phase 1/2a study for dry AMD, with integration of new retinal pigment epithelium cells observed. This indicates potential efficacy for OpRegen, aimed at addressing unmet medical needs in AMD treatment. The webinar will present detailed results and anatomical improvements related to OpRegen therapy.

Lineage Cell Therapeutics (LCTX) reported positive outcomes in its Phase 1/2a study of OpRegen for treating dry age-related macular degeneration (AMD). Restoration of retinal tissue was observed in two Cohort 4 patients, with significant improvements in visual acuity noted within six months. This suggests that atrophic AMD may not be irreversibly degenerative. The company has also filed a PCT patent application to protect these findings. The therapy demonstrated safety with no unexpected adverse events over more than five years of follow-up.

Lineage Cell Therapeutics, a clinical-stage biotech company, reported Q1 2021 financial results with total revenues of approximately $0.4 million, down from $0.5 million in Q1 2020, mainly due to decreased grant income. Operating expenses decreased to $7.3 million, while R&D expenses increased slightly to $3.4 million. The net loss attributable to Lineage was $1.4 million, improved from a $8.4 million loss in Q1 2020. The company highlighted operational progress in its clinical programs, particularly OpRegen, associated partnerships, and a strong cash position of $62.4 million.

Lineage Cell Therapeutics (LCTX) appointed Anula Jayasuriya, M.D., Ph.D., M.B.A., to its Board of Directors effective May 4, 2021. Dr. Jayasuriya brings extensive expertise as a healthcare investment executive and venture capitalist, with a focus on women's health. She founded EXXclaim Capital and co-founded the Evolvence India Life Science Fund. The appointment is aimed at enhancing the board's diverse expertise as Lineage pursues advancements in cell therapy and regenerative medicine with potential multi-billion-dollar market opportunities.

Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) will announce its Q1 2021 financial and operating results on May 13, 2021, after U.S. markets close. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Interested parties can join the call by dialing the provided numbers or accessing the webcast online. Lineage specializes in allogeneic cell therapies for unmet medical needs, with significant clinical programs in retinal, spinal, and immuno-oncology treatments.

Lineage Cell Therapeutics (LCTX) presented updated interim results from its Phase 1/2a study of OpRegen at the ARVO 2021 conference. The treatment focuses on dry age-related macular degeneration (AMD) with geographic atrophy. Findings showed that 83% of Cohort 4 patients maintained or improved their visual acuity, with some achieving up to +19 letters on the ETDRS chart. The therapy demonstrated significant potential, especially with earlier intervention. No unexpected adverse events were reported, indicating OpRegen's favorable safety profile. This data supports ongoing development of OpRegen as a leading treatment option.

Lineage Cell Therapeutics (NYSE American: LCTX) announced that CEO Brian M. Culley will present at the B. Riley Securities’ Neuroscience Conference on April 28, 2021, at 1:30 p.m. ET. The presentation will be a virtual fireside chat hosted by B. Riley Equity Research. Interested investors can access the live and archived webcast on the Events and Presentations section of Lineage’s website.